Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

Journal of Clinical Oncology

Volumn 28, Issue 19, 2010, Pages 3107-3114

  Monk, Bradley J ^a   Herzog, Thomas J ^a   Kaye, Stanley B ^a   Krasner, Carolyn N ^a   Vermorken, Jan B ^a   Muggia, Franco M ^a   Pujade Lauraine, Eric ^a   Lisyanskaya, Alla S ^a   Makhson, Anatoly N ^a   Rolski, Janusz ^a   Gorbounova, Vera A ^a   Ghatage, Prafull ^a   Bidzinski, Mariusz ^a   Shen, Keng ^a   Ngan, Hextan Yuen Sheung ^a   Vergote, Ignace B ^a   Nam, Joo Hyun ^a   Park, Youn Choi ^a   Lebedinsky, Claudia A ^a   Poveda, Andrés M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; PLATINUM; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RECURRENT OVARY CANCER; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKOPENIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; STOMATITIS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 77955491837     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.4037     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. du Bois A, Quinn M, Thigpen T, et al: 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16:viii7-viii12, 2005 (suppl 8)
3. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006 (Pubitemid 43048949)
4. Copeland LJ: Epithelial ovarian cancer, in Di- Saia PJ, Creasman WT (eds): Clinical Gynecologic Oncology (ed 7). Philadelphia, PA, Elsevier, 2007, pp 313-367
5. Bast RC, Thigpen JT, Arbuck SG, et al: Clinical trial endpoints in ovarian cancer: Report of an FDA/ ASCO/AACR Public Workshop. Gynecol Oncol 107: 173-176, 2007 (Pubitemid 47575741)
6. Carter NJ, Keam SJ: Trabectedin: A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67:2257-2276, 2007 (Pubitemid 47557097)
7. Schöffski P, Casali PG, Taron M, et al: DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). J Clin Oncol 24:525s, 2006 (suppl; abstr 9522)
8. Sessa C, De Braud F, Perotti A, et al: Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867-1874, 2005
9. Krasner CN, McMeekin DS, Chan S, et al: A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97: 1618-1624, 2007 (Pubitemid 350249358)
10. von Mehren M, Schilder RJ, Cheng JD, et al: A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 19:1802-1809, 2008
11. Takahashi N, Li WW, Banerjee D, et al: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 7:3251-3257, 2001 (Pubitemid 32963850)
12. Meco D, Colombo T, Ubezio P, et al: Effective combination of ET-743 and doxorubicin in sarcoma: Preclinical studies. Cancer Chemother Pharmacol 52:131-138, 2003 (Pubitemid 37041346)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
14. Donald S, Verschoyle RD, Greaves P, et al: Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743). Cancer Res 63:5902-5908, 2003 (Pubitemid 37187491)
15. 2006 Update of ASCO practice guideline recommendations for the use of white blood cell growth factors: Guideline summary. J Clin Oncol Pract 2:196-201, 2006
16. Cancer Therapy Evaluation Program: National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, August 9, 2006. http://ctep.cancer.gov
17. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993 (Pubitemid 23073154)
18. Greimel E, Bottomley A, Cull A, et al: An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39:1402-1408, 2003 (Pubitemid 36773783)
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
21. Krasner CN, Poveda A, Herzog T, et al: Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol 27:283s, 2009 (suppl; abstr 5526)
22. Temple R: Hy's law: Predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15:241-243, 2006
23. National Comprehensive Cancer Network: The NCCN Clinical Practice Guidelines in Oncology Ovarian Cancer (version 1.2009). http://www.nccn.org
24. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
25. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001 (Pubitemid 32642183)
26. Gordon AN, Tonda M, Sun S, et al: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1-8, 2004 (Pubitemid 39286270)
27. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVA-2.2 trial. Lancet 361:2099-2106, 2003
28. Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707, 2006 (Pubitemid 46630933)